Shares of Nemus Bioscience Inc (OTCMKTS:NMUS – Get Free Report) fell 9.5% during mid-day trading on Tuesday . The company traded as low as $0.60 and last traded at $0.65. 1,004,500 shares changed hands during mid-day trading, an increase of 166% from the average session volume of 377,395 shares. The stock had previously closed at $0.72.
Nemus Bioscience Stock Down 9.5 %
The firm has a 50 day simple moving average of $4.13.
About Nemus Bioscience
Nemus Bioscience, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus.
Read More
- Five stocks we like better than Nemus Bioscience
- The 3 Best Retail Stocks to Shop for in August
- Beyond NVIDIA: Top 5 Semiconductor Stocks to Watch for 2025
- Insider Trading – What You Need to Know
- Netflix Is On Track To Hit $1,000 By Christmas
- Overbought Stocks Explained: Should You Trade Them?
- UMAC Stock Climbs Amid Trump Jr. Appointment and Meme Stock Hype
Receive News & Ratings for Nemus Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemus Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
